CORRIGENDUM

Dendritic cell vaccination for cancer therapy

Frank O Nestle

Correction to: *Oncogene* (2000) **19**, 6673–6679.

Following publication of the above paper, the author has identified errors in Table 1. The correct version of Table 1 is reproduced below.

Table 1 Summary of published trials in DC vaccination (for details see text)

<i>Investigator</i>	<i>Tumor</i>	<i>Source</i>	<i>Antigen</i>	<i>Route</i>	<i>Tu antigen specific immune response</i>	<i>Objective clinical response</i>
Nestle, Schadendorf	Melanoma	Monocytes	MelanA, gp100, tyrosinase, Tulys	Intranodal	yes	yes
Lotze	Melanoma	Monocytes	MelanA, gp100, tyrosinase	i.v.	no	yes
Panelli, Marincola	Melanoma	Monocytes	MelanA, gp100	i.v.	yes	yes
Thurner, Schuler	Melanoma	Monocytes	MAGE-3	i.d., i.v.	yes	no
Mackensen	Melanoma	CD34	MelanA, gp100, tyrosinase	i.v.	yes	no
Hörtl, Thurnher	RCC	Monocytes	Tulys	i.v.	yes	no
Levy, Engleman	Lymphoma	DC blood precursors	idiotype	i.v.	yes	yes
Murphy, Salgaller	Prostate	Monocytes	PSMA	i.v.	yes	yes
Burch, Vuk-Pavlovic	Prostate	DC blood precursors	PAP-GMCSF fusion protein	i.v.	yes	yes
Morse, Lyerly	Various	Monocytes	CEA	i.v.	no	no

Tulys = tumor lysate, PAP = prostatic acid phosphatase